Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NECESSITY trial in primary Sjögren's syndrome
NL-OMON55055Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in primary Sjögren's syndrome comparing Hydroxychloroquine + leflunomide, Hydroxychloroquine + mycophenolate mofetil and Placebo (3 arms). Primary endpoints: Preliminary STAR response at week 24 in cohort 1 and Preliminary STAR response at week 24 in cohort 2. Started Sep 2023; status: recruiting.
02
Drugs
hydroxychloroquineleflunomidemycophenolate mofetil
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on NL-OMON55055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55055.